Generic Drug Maker Hindustan Laboratories Submits IPO Papers to SEBI
Hindustan Laboratories Limited has submitted its DRHP to SEBI for a proposed initial public offering of equity shares.
The issue consists of a fresh issue of up to 5,000,000 equity shares and an offer for sale of up to 9,100,000 equity shares, aggregating to a total issue size of up to 14,100,000 equity shares of face value ₹10 each. The promoters include Rajesh Vasantray Doshi, Kunjal C. Dedhia and Krishiv Rajesh Doshi.
As per the filing, the company intends to use the net proceeds from the fresh issue to meet working capital requirements and for general corporate purposes.
Hindustan Laboratories operates in the pharmaceutical sector and focuses on the manufacture and supply of generic medicines primarily to government customers under B2G contracts. Its supply network includes central government procurement agencies and state government bodies.
The company’s product portfolio spans multiple therapeutic segments, addressing both acute and chronic conditions. It distributed its products across 27 states and Union Territories during FY25 and the six months ended September 30, 2025.
The equity shares offered through the Red Herring Prospectus are proposed to be listed on the BSE and NSE. Choice Capital Advisors Private Limited is acting as the book running lead manager.
